Articles producció científica> Medicina i Cirurgia

Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice

  • Datos identificativos

    Identificador: PC:1546
    Autores:
    Jorge JovenAnabel García-HerediaMarta Riera-BorrullIsabel Fort-GallifaFedra Luciano-MateoNoemí CabréAnna Hernandez-AguileraJordi Camps
    Resumen:
    Metformin is the first-line pharmacological treatment of diabetes. In these patients, metformin reduces body weight and decreases the risk of diabetes-related complications such as cardiovascular disease. However, whether metformin elicits beneficial effects on liver histology is a controversial issue and, as yet, there is no consensus. Paraoxonase-1 (PON1), an enzyme synthesized mainly by the liver, degrades lipid peroxides and reduces oxidative stress. PON1 activities are decreased in chronic liver diseases. We evaluated the effects of metformin in the liver of PON1-deficient mice which, untreated, present a mild degree of liver steatosis. Metformin administration aggravated inflammation in animals given a standard mouse chow and in those fed a high-fat diet. Also, it was associated with a higher degree of steatosis in animals fed a standard chow diet. This report is a cautionary note regarding the prescription of metformin for the treatment of diabetes in patients with concomitant liver impairment.
  • Otros:

    Autor según el artículo: Jorge Joven; Anabel García-Heredia; Marta Riera-Borrull; Isabel Fort-Gallifa; Fedra Luciano-Mateo; Noemí Cabré; Anna Hernandez-Aguilera; Jordi Camps
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: JOVEN MARIED, JORGE; Anabel García-Heredia; Marta Riera-Borrull; Isabel Fort-Gallifa; Fedra Luciano-Mateo; Noemí Cabré; Anna Hernandez-Aguilera; CAMPS ANDREU, JORGE
    Palabras clave: metformin Paraoxonase Antioxidants
    Resumen: Metformin is the first-line pharmacological treatment of diabetes. In these patients, metformin reduces body weight and decreases the risk of diabetes-related complications such as cardiovascular disease. However, whether metformin elicits beneficial effects on liver histology is a controversial issue and, as yet, there is no consensus. Paraoxonase-1 (PON1), an enzyme synthesized mainly by the liver, degrades lipid peroxides and reduces oxidative stress. PON1 activities are decreased in chronic liver diseases. We evaluated the effects of metformin in the liver of PON1-deficient mice which, untreated, present a mild degree of liver steatosis. Metformin administration aggravated inflammation in animals given a standard mouse chow and in those fed a high-fat diet. Also, it was associated with a higher degree of steatosis in animals fed a standard chow diet. This report is a cautionary note regarding the prescription of metformin for the treatment of diabetes in patients with concomitant liver impairment.
    Grupo de investigación: Unitat de Recerca Biomèdica
    Áreas temáticas: Ciències de la salut Ciencias de la salud Health sciences
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0009-2797
    Identificador del autor: orcid.org/0000-0003-2749-4541; N/D; N/D; N/D; N/D; N/D; N/D; N/D
    Fecha de alta del registro: 2016-05-24
    Página final: 63
    Volumen de revista: 249
    Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
    Enlace a la fuente original: https://www.sciencedirect.com/science/article/abs/pii/S0009279716300679
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: 10.1016/j.cbi.2016.03.004
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2016
    Página inicial: 56
    Tipo de publicación: Article Artículo Article
  • Palabras clave:

    Metformina
    Antioxidants
    Paraoxonasa
    metformin
    Paraoxonase
    Antioxidants
    Ciències de la salut
    Ciencias de la salud
    Health sciences
    0009-2797
  • Documentos:

  • Cerca a google

    Search to google scholar